Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 10/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8245438 | 0.90 | BACE1 (0.59) | BACE1ALDH1A1HPGDKDM4EROCK2 | |
| SCHEMBL8249355 | 0.84 | BCAT2 (0.54) | ALDH1A1HPGDKDM4EROCK2GAA | |
| SCHEMBL8247171 | 0.82 | BCAT2 (0.53) | ALDH1A1HPGDKDM4ENPC1 | |
| SCHEMBL7947891 | 0.81 | BACE1 (0.48) | BACE1ALDH1A1ROCK2GAAPKM | |
| SCHEMBL13229761 | 0.81 | BACE1 (0.59) | BACE1ALDH1A1ROCK2GAAPKM | |
| SCHEMBL13229689 | 0.81 | ALDH1A1 (0.53) | ALDH1A1HPGDKDM4EROCK2GAA | |
| SCHEMBL7946598 | 0.80 | ALDH1A1 (0.54) | ALDH1A1HPGDROCK2GAAPKM | |
| SCHEMBL3886906 | 0.80 | ALDH1A1 (0.54) | BACE1ALDH1A1HPGDROCK2GAA | |
| SCHEMBL3886903 | 0.80 | ALDH1A1 (0.54) | BACE1ALDH1A1HPGDROCK2GAA | |
| SCHEMBL13229356 | 0.78 | GPR139 (0.63) | ALDH1A1HPGDGAAPKMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168070-A1 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | HEINE NIKLAS | 2010-07-01 | — | — | US | disclosed |
| US-20100168070-A1 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | HEINE NIKLAS | 2010-07-01 | — | — | US | disclosed |
| US-20100144681-A1 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM INTERNATION GMNB (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144681-A1 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM INTERNATION GMNB (DE) | 2010-06-10 | — | — | US | disclosed |
| WO-2007017511-A2 | COMPOUNDS FOR TREATING ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007017510-A2 | ISOPHTHALIC ACID DIAMIDES FOR TREATING ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168070-A1 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | PSEN1, PSEN2, ADORA3 | BACE1 5/4885ALDH1A1 206/4885HPGD 1079/4885 |
| US-20100144681-A1 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | PSEN1, PSEN2, ADORA3 | BACE1 5/4885ALDH1A1 232/4885HPGD 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.